Cancer risk in patients with pulmonary fibrosis and a rare telomere related gene variant

Abstract

Background Rare telomere related gene (TRG) variants are the cause of telomere biology disorders (TBD), a broad spectrum of age-related diseases, such as pulmonary fibrosis (PF) a disease manifesting at older age. TBD patients are at increased risk of certain types of squamous cell carcinomas and hematological malignancies. However, most studies on cancer incidence in TBDs involved relatively young cohorts in which patients with pulmonary fibrosis were underrepresented or absent. Therefore, we investigated cancer incidence in patients with pulmonary fibrosis as major manifestation of TBD (TBD-PF) with a pathogenic (P), likely pathogenic (LP), and variant of unknown significance (VUS) TRG-variant and compared it to the general population. Methods TBD-PF patients (n = 177) were retrospectively included and cancer history was collected. For each cancer type the observed number of cancers was compared with the expected number adjusted for age and sex based on data of the Netherlands Cancer Registry. Results The TBD-PF cohort (median age 62.8 years, 63% male), consisted of 114 P/LP and 63 VUS carriers. Restricting the analyses to P/LP variant carriers we observed 14 patients with cancer (solid cancer n = 8 (7.0%); hematological cancer n = 6 (5.3%)). The observed all-cancer incidence (12.3%) was comparable to expected (18.9%) in the general population, Observed/Expected incidence 0.6 (95%CI 0.4-1.0). Regarding cancer types, only myelodysplastic syndrome was significantly more frequently observed than expected (Observed/Expected = 56 (95%CI 21–117)). There were no significant differences in clinical characteristics and transplant-free survival between TBD-PF patients with and without cancer. Comparable results were obtained when patients with TRG variants classified as VUS were included. Conclusion All-cancer risk for TBD-PF patients was comparable to the general population. However, TBD-PF patients have an increased risk of developing myelodysplastic syndrome, underlining the importance of tailored genetic counselling and hematological surveillance.